课题基金 / 基金详情

Investigating the Role of Somatic Mutations in Arteriovenous Malformations

Investigating the Role of Somatic Mutations in Arteriovenous Malformations
研究体细胞突变在动静脉畸形中的作用
批准号:
10410345
负责人:
Daniel Snellings
金额:
$3.35万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-06-01 至 2022-04-11

项目摘要

项目成果

Daniel Snellings的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结 遗传性出血性毛细血管扩张症(HHT)是孟德尔人的一种疾病,其特点是 多发性局灶性血管畸形(VM),包括大脑中的大型内脏动静脉畸形, 肝、肺;粘膜和皮肤组织内大量毛细血管扩张。这些VM是曲折的 血管聚集,导致动脉和静脉系统之间的血液直接高流量分流。 与HHT相关的VM通常会导致急性出血、慢性出血、贫血、中风、心脏和肝脏衰竭。 尽管与HHT相关的发病率和死亡率很高,但仍然没有有效的药物疗法来治疗 治疗HHT相关的VM;唯一的治疗方法是手术栓塞或切除。这些外科治疗不起作用 治疗疾病的源头,有大量的VM在手术切除后重新生长的案例。此外, 这些治疗是为最大的虚拟机保留的;但是,患有HHT的个人有大量的小型虚拟机 它经常出血,仍然是一个重大的、但无法治疗的医疗问题。几十年的研究已经证明 重点是了解与HHT相关的VM的潜在遗传学和血管生物学,然而 启动VM的分子事件仍然知之甚少。这项建议的总体目标是获得 对引发血管畸形的分子事件有基本的了解。我们早就知道, HHT是由ENG、ACVRL1或Smad4的常染色体显性功能丧失突变引起的。这些 研究结果导致人们相信,与HHT相关的VM是由突变基因的单倍体不足造成的;然而, 这一机制不能解释为什么HHT相关的VM是严格意义上的局灶性病变,尽管 突变。与单倍体功能不全假说相反,我已经确定与HHT相关的VM含有一个体细胞 与原因生殖系突变相同的基因突变导致双等位基因功能丧失 产品。这些突变符合克努德森的两次击打机制,强烈支持功能性 体细胞突变在HHT相关VM发病机制中的作用。这项提案的目的建立在这一发现的基础上 目的是了解这些体细胞突变如何损害血管发育从而导致血管 畸形。这些具体目标的成功完成将填补我们长期存在的关键空白 了解HHT生物学,并可能确定对治疗干预敏感的新分子/途径。 目的1:鉴定突变细胞类型并确定畸形中嵌合体的程度。 目的:阐明体细胞突变对突变型和野生型细胞的功能影响。 目的3:询问散发性和遗传性脑VM中是否存在体细胞突变。
英文摘要
PROJECT SUMMARY Hereditary Hemorrhagic Telangiectasia (HHT) is a Mendelian disease characterized by the development of multiple focal vascular malformations (VMs) including large visceral arteriovenous malformations in the brain, liver, and lungs; and numerous telangiectasia in mucosal and cutaneous tissue. These VMs are tortuous collections of vessels that result in the direct high-flow shunting of blood between arterial and venous systems. HHT-related VMs often lead to acute hemorrhage, chronic bleeding, anemia, stroke, heart and liver failure. Despite the morbidity and mortality associated with HHT, there remains no effective pharmaceutical therapy to treat HHT-related VMs; the only therapy is surgical embolization or resection. These surgical treatments do not treat the source of the disease and there are numerous cases of VM regrowth after surgical resection. In addition, these treatments are reserved for the largest VMs; however, individuals with HHT have a multitude of small VMs which frequently bleed and remain a significant, yet untreatable, medical problem. Decades of research have focused on understanding the underlying genetics and vascular biology of HHT-related VMs, however the molecular events that initiate VMs remain poorly understood. The overall objective of this proposal is to gain a fundamental understanding of the molecular events that initiate vascular malformation. We have long known that HHT is caused by autosomal dominant loss-of-function mutations in either ENG, ACVRL1, or SMAD4. These findings led to the belief that HHT-related VMs results from haploinsufficiency of the mutated gene; however, this mechanism does not account for why HHT-related VMs are strictly focal lesions despite the systemic mutation. Counter to the haploinsufficiency hypothesis, I have identified that HHT-related VMs harbor a somatic mutation in the same gene as the causal germline mutation resulting in biallelic loss-of-function of the gene product. These mutations are consistent with a Knudsonian two-hit mechanism, strongly supporting a functional role for somatic mutations in the pathogenesis of HHT-related VMs. The aims of this proposal build on this finding with the goal of understanding how these somatic mutations impair vascular development to result in vascular malformation. Successful completion of these specific aims will fill a long-standing critical gap in our understanding of HHT biology and may identify new molecules/pathways susceptible to therapeutic intervention. Aim 1: Identify the mutant cell type and determine the extent of mosaicism in the malformation. Aim 2: Elucidate the functional effects of the somatic mutation on mutant and wild-type cells. Aim 3: Interrogate the presence of somatic mutations in sporadic and hereditary brain VMs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Investigating the Role of Somatic Mutations in Neurofibromatosis Brain
  • 批准号:
    10722624
  • 项目类别:
  • 资助金额:
    $7.01万
  • 财政年份:
    2023
  • 负责人:
    Daniel Snellings
  • 依托单位:
海外基金